You are here: Industry Insights > FabiFlu

News List

Glenmark releases interim data from PMS Study on Favipiravir (FabiFlu) expresspharma
June 09, 2021
PMS interim data revealed no new safety signals or concerns till date and safety is in line with known side effects of the drug.
Favipiravir shows significant improvement in time to clinical cure for mild to moderate COVID-19 expresspharma
November 25, 2020
These findings were observed in Phase 3 clinical trial conducted by Glenmark Pharmaceuticals and have been published by the International Journal of Infectious Diseases.
Glenmark to launch FabiFlu (400 mg) for COVID-19 treatment expresspharma
August 07, 2020
With the new 400 mg version, patients need to consume nine tablets on Day 1, and thereafter two tablets twice a day from Day 2 till the end of the course.
FabiFlu more affordable than other drugs: Glenmark to DCGI expresspharma
July 22, 2020
The company also sends its justifications and clarifications to allegations of false claims about FabiFlu’s use for COVID-19 patients.
DCGI queries pharma company on its claim of FabiFlu use for COVID-19 patients with comorbidities expresspharma
July 21, 2020
As per statement by the Glenmark and media reports, the DCGI had accelerated the process for clinical trials and reviews considering the pandemic situation, unmet medical conditions and unavailability of specific therapeutic management against COVID-19...
Glenmark Pharma cuts price of COVID-19 drug by 27 pc to Rs 75/tablet expresspharma
July 14, 2020
Glenmark Pharmaceuticals had launched FabiFlu last month at a price of Rs 103 per tablet.